Doctors often compare different treatments for Chronic Obstructive Pulmonary Disease (COPD). Triple therapy combines three medicines: two bronchodilators and one inhaled corticosteroid. Dual bronchodilator therapy uses only two bronchodilators. Researchers want to know which approach works better for patients.
Recent large clinical trials provide important answers. The IMPACT, ETHOS, and KRONOS trials studied thousands of COPD patients. These studies compared triple therapy with dual bronchodilator therapy in a systematic way.
Triple therapy reduces exacerbations more effectively.
Patients on triple therapy experienced fewer flare-ups. These flare-ups are dangerous because they worsen breathing and often require hospital care. Moreover, triple therapy showed better results in preventing severe exacerbations.
Additionally, triple therapy improves lung function. Patients achieved higher FEV1 values compared to those on dual therapy. Better lung function helps people breathe more easily during daily activities.
Furthermore, triple therapy enhances quality of life. Patients reported less breathlessness and greater ability to perform routine tasks. They also needed fewer rescue inhalers.
However, doctors must consider the risks. Triple therapy includes corticosteroids, which can increase the chance of pneumonia in some patients. Dual bronchodilator therapy shows a better safety profile in certain cases.
The IMPACT trial focused on patients with a history of frequent exacerbations. ETHOS and KRONOS provided data across different COPD severity levels. All three trials support the use of triple therapy for high-risk patients.
In conclusion, triple therapy offers clear advantages in reducing exacerbations, improving lung function, and enhancing quality of life. Still, treatment decisions should be individualised. Doctors must evaluate each patient’s exacerbation history, eosinophil levels, and overall health before choosing between triple and dual therapy.
This comparative analysis helps physicians make better treatment choices for COPD patients.